Clinical guidelines exist for the treatment of chronic epilepsy and epilepsy in women 2 . This publication provides guidance for the clinician investigating and managing epilepsy in adults who have an intellectual disability as defined by an Intelligence Quotient (IQ) of less than 70, onset in the developmental period and difficulties with adaptive functioning.
INTRODUCTION
Studies suggest that as many as one fifth of the population of people with intellectual disabilities across the lifespan have epilepsy 3 . Higher prevalence figures are quoted in institutional settings and with decreasing IQ [4] [5] [6] .
Uncontrolled seizures have a profound impact on the quality of life of individuals and carers alike [7] [8] [9] [10] [11] . Furthermore, the management of epilepsy in people with an intellectual disability provides special challenges. Key factors in this include the aetiology and severity of the epilepsy, a limited evidence base for interventions and difficulties in investigation and communication.
Guidelines exist for the management of epilepsy in the general population 1 and for women with epilepsy 2 . Specific guidelines for the management of epilepsy in the intellectually disabled are not available. In recognition of this, the special interest research group for health of the International Association for the Scientific Study of Intellectual Disability (IASSID) created a working group to establish guidelines for the management of epilepsy in this population.
GUIDELINE DEVELOPMENT GROUP
This multiprofessional international group included clinical psychologists, clinical neurophysiologists, intellectual disability nurses, neurologists, paediatric neurologists, neuropsychiatrists, intellectual disability psychiatrists and representatives of carer groups.
SCOPE OF THE GUIDELINES
These guidelines have been developed taking into account the individual characteristics of the person with epilepsy, difficulties in diagnostic investigations and the lack of controlled trials in intellectual disability during drug development. Through consultation, a consensus view on the management of epilepsy in adults with an intellectual disability has been achieved. In order to recognize the multiprofessional nature of care for the disabled group the guidelines could be applicable to both clinicians and service providers.
EVIDENCE REVIEW AND SYNTHESIS
Medline and Psychlit searches were performed on epilepsy and intellectual disability, mental handicap and mental retardation (please refer to Appendix 1). Additional references were followed up from individual papers. Key intellectual disability journals were also hand searched for relevant articles. Additional information was sourced from the guideline development group.
As will be seen there are major gaps in the evidence base for this field. Where these gaps were recognized, consensus group opinion was sought.
Levels of evidence
In the following text, statements and recommendations are made. In the case of interventional studies these are assigned a level of evidence based on a recognized evidence classification system 12 . Recommendations were characterized according to their strength on the same framework. In addition, the panel recognized the paucity of studies directly performed on samples of individuals from adult intellectual disability populations. Therefore, each level of evidence and recommendation is graded according to the sample population from which the data was derived. These are described in Table 1 . 
THE INDIVIDUAL
Characteristics of the individual with an intellectual disability will impact on the diagnostic process, assessment and the implementation of management plans. Factors that would make management difficult include:
(1) The aetiology of the intellectual disability.
(2) The severity of the intellectual disability.
(3) Psychiatric and behavioural problems.
(4) Recognized and unrecognized physical health problems.
(5) Swallowing and feeding difficulties.
(6) Communication difficulties and the individual's ability to understand the treatment.
(7) The capacity to make an informed choice.
Aetiology
The aetiology of the intellectual disability may highlight characteristics of the epilepsy including the seizure type. This is thought to be the case in some genetically determined conditions associated with intellectual disability; for example, in Angelman's syndrome the seizure type is believed to be of a cryptogenic generalized nature 13 and in the Fragile X syndrome features similar to benign epilepsy with centrotemporal spikes may be seen 14 .
Severity
An assessment of the individual's level of ability can be an important guide to the likely severity of the epilepsy and a pointer to other comorbid features 5, 15 . When assessing severity the clinician should not overlook the possibility that the individual has a state-dependent learning disability where the severity of the apparent learning disorder has been complicated by the frequency of the seizures or, in some cases, by the presence of unrecognized non-convulsive status epilepticus.
Psychiatric and behavioural problems
Studies have found rates of behaviour disturbance and psychiatric disorder to be significantly higher in people with intellectual disabilities than in the general population [16] [17] [18] [19] . It is less clear as to whether this is due to their epilepsy or whether the presence of epilepsy is merely a marker for increased behavioural or psychiatric morbidity in the intellectually disabled population 20 . In clinical practice however there will frequently be concerns that:
(1) A behavioural disturbance may be a manifestation of epilepsy.
(2) Epilepsy treatment may worsen an existing behavioural problem.
(3) A behavioural problem may be caused by the epilepsy treatment.
(4) The interaction between antiepileptic medication and psychiatric treatments.
Physical health problems
Up to one third of people with an intellectual disability have an associated physical disability, most often cerebral palsy. This may put them at risk of injury during seizures (particularly dislocation). Swallowing and feeding difficulties are also common and are associated with gastro-oesophageal reflux, an important consideration when choosing the preparation of antiepileptic medication. Many individuals with an intellectual disability often have unrecognized physical morbidity 21 . Hearing and vision are two problem areas frequently overlooked, up to one third have poor eyesight and 40% have a problem with hearing. These two problems increase with increasing age and may also lead to difficulties in drug administration. Physical disabilities are an important consideration when formulating a treatment plan as they may act as a marker of potential early mortality.
Communication and capacity
Some degree of difficulty with communication is inevitable in an individual with an intellectual disability. Difficulties with communication can lead to difficulties in history taking and examination 22, 23 . Many individuals with an intellectual disability will be handicapped by their communication difficulties and will be unable to take an active part in the decision-making process. It is important to note the capacity each individual has to make decisions about their treatment.
Where they are unable to participate in the decisionmaking process they should not be penalized by this, but should have access to the most appropriate treatment for their epilepsy.
The individual-statements and recommendations.
• Any individual being assessed for the presence of epilepsy or being treated for epilepsy should have a comprehensive evaluation of their current abilitites, health status and presence of co-morbidity.
• Any individual being assessed for the presence of epilepsy or being treated for epilepsy should have a recording of any current psychiatric or behavioural problem.
• Any individual being assessed for the presence of epilepsy or being treated for epilepsy should have an assessment of their ability to understand and communicate and their capacity to make informed choice.
INVESTIGATIONS
The core investigation in the diagnosis of epilepsy in a patient with an intellectual disability is, as in the general population, the clinical history-with an emphasis on witness description of seizure. The hallmark of the epileptic phenomenon is the paroxysmal nature of the disorder-brief, episodic changes should be described. However, the special characteristics of this population make the gathering and interpretation of these data more complex. In particular, the communicative abilities of the individual may make the recognition of aura and post-ictal phenomena difficult. Furthermore, diagnostic overshadowing is common and an expectation for either behaviour or seizure disorder may influence the objectivity of both carers and professionals when reporting events. A particularly difficult issue arises over the differential diagnosis of behaviour and epilepsy. It is possible that the clinician may be called upon to assess whether behavioural outbursts or repetitive manneristic movements have an epileptic basis; this is complicated by the high frequency of behaviour problems and mannerisms in this population [24] [25] [26] . As many as 20-25% of patients referred to a specialist epilepsy unit have a misdiagnosis of epilepsy.
Syncope, non-epileptic seizures, panic attacks, hallucinations and movement disorders may be mistaken for seizures but may also coexist in an individual diagnosed with epilepsy. When evaluating an individual's epilepsy the possibility of alternative explanations for these events should be considered.
Clear unbiased reporting is essential and carers may need education in performing and in describing their observations. Behavioural descriptions of seizure events, written by such eyewitnesses, are essential in clinical practice, both to aid the clinician in diagnosis and for accurate tracking of seizure frequency 27 . These behavioural descriptions should be entered in seizure diaries, which should be kept with the individuals at all times. This is important since the majority of people with intellectual disabilities have multiple carers across a range of care settings. Video recording of events may further aid diagnosis 28 . In cases of behavioural outbursts a functional analysis of behaviour may also help in differentiating a behaviour from a seizure.
As in the general population with epilepsy, electroencephalography (EEG) may aid in seizure and seizure syndrome diagnosis. Video EEG and telemetry remain important diagnostic tools for the individual with intellectual disability, however these may not be readily available. Some abnormal movements in people with epilepsy may mimic seizures but on video EEG these have been demonstrated to be non-seizure related 29 . Observed behaviour may be attributed to epilepsy, particularly in the severely or profoundly disabled patient. Staring and abnormal motor activity have often been reported as epileptic activity which, on subsequent video EEG, has been demonstrated to be non-epileptic 60% of the time 30, 31 . The EEG may be of particular value in those with chronic epilepsy, where despite adequate treatment, individuals are still suffering regular seizure-like movements.
There is a high prevalence of abnormality found on neuroimaging and in particular magnetic resonance imaging (MRI) 32 . Patients with intellectual disabilities may have difficulties co-operating with the technicians in the MRI suite and may, therefore, need sedation or generalized anaesthesia.
Investigations-recommendations and statements.
• Individuals with an intellectual disability should have access to the full range of electrophysiological and neuroimaging investigations.
• Facilities should be available for imaging under general anaesthesia.
• Where doubt exists as to the diagnosis of a behavioural outburst, video recording and functional analysis of behaviour is recommended prior to treatment.
SEIZURE AND SYNDROME DIAGNOSIS
The identification of both seizure type and seizure syndrome has implications for therapeutic interventions and prognosis. Individuals with an intellectual disability are particularly likely to have associated syndromal diagnosis such as the Lennox-Gastaut syndrome, infantile myoclonic epilepsies 33 or have suffered from infantile spasms (Trevathan et al. 34 ).
The guidelines for the treatment of the severe epilepsy syndromes of childhood such as West syndrome, Laundau Kleffner syndrome, CSWS (continuous spike-wave discharges during slow wave sleep) syndrome, Rasmussen syndrome, early myoclonic encephalopathy and early infantile epileptic encephalopathy or Ohtohara syndrome are not included in this paper due to the focus on adulthood. These are under analysis to be reported later.
Seizure and syndrome diagnosis-recommendations and statements.
• All individuals should have, where possible, seizure type and syndrome classified as per the ILAE classification.
TREATMENT HISTORY
Health professionals caring for patients with an intellectual disability commonly complain that insufficient data exist on the individual's past history 21 . This may be related to the communication difficulties of the individual and the need for information to come from carers. This is often exacerbated if an individual has had many changes in accommodation or if different carers attend each appointment. Past response to medication should also be available to the clinician as this may guide treatment choice, interpretation of side effects and assessment of the severity of the individual's epilepsy.
Treatment history-recommendations and statements.
• All patients with epilepsy and intellectual disability should have available full treatment histories for clinical consultation. 50 Motte et al. 51 1 2 (1.1) (2.4) Sachdeo et al. 52 1 3 (1.3) (2.7) Crawford et al. 53 1 1 (0) (0) Kaski et al. 54 1 2 (1.42) (2.5) Siegel et al. 55 2 2 (1.57) (2.3) Pitkanen et al. 56 2 1 (2) (1.14) Matilainen et al. 57 2 2 (2.1) (1.57) Linuma et al. 58 2 2 (2.14) (2.4) Gaily et al. 59 2 2 (2.4) 
THE CARE CONTEXT
A great diversity exists as to the care context of individuals with epilepsy and intellectual disability. Individuals may live alone with support, be cared for at home by relatives, be in community-based group homes or reside in institutions. Evidence from the broader research on intellectual disability would suggest that the care setting is important in behavioural disorders [35] [36] [37] . Furthermore, training levels and standards in residential settings will impact on the outcome of some medical interventions such as attempted medication reduction in individuals on psychotropic medication 38 .
In addition, carer knowledge and the level of staff support may impact on their ability to follow through epilepsy-related interventions. This may be particularly true when rectal diazepam is indicated for prolonged seizures. The Epilepsy Knowledge Profile may be a useful tool for the appraisal of carers' knowledge about both social and medical aspects of epilepsy 39 .
The care context-statements and recommendations.
• An assessment of the individual's level of support, and the ability of that support to work with epilepsy management plans should be assessed in all individuals with epilepsy and intellectual disability.
ASSESSING THE IMPACT OF EPILEPSY
Epilepsy may profoundly affect the lives of patients through effects on cognition 40 , falls and fractures 41 , hospitalization 42 and increased mortality [43] [44] [45] [46] . Unpublished research also suggests carers may also be affected through an increased carer burden 47 . Establishing a baseline for the current impact of epilepsy will be a composite of measures covering: Increasing research into these broader issues has led to the development of scales designed to measure carer, staff and patient views 11, 48 .
The impact of epilepsy-recommendations and standards.
• A full assessment of how epilepsy is affecting an individual should be undertaken before management change is initiated. The assessment should include evidence of impact on cognitive functioning and physical health.
• An assessment of the impact of epilepsy on the family or carers should be carried out, using where possible appropriate validated measures.
TREATMENT OPTIONS
Guidelines already exist as to the management of epilepsy in adults without intellectual disability 1 . Meta-analysis of trial data has failed to show significant differences between compounds in add-on situations 49 . This section will address the use of anticonvulsants in clinical situations:
(1) Treatment of generalized seizures (absence, primary generalized tonic-clonic, myoclonic seizures).
(2) Management of Lennox-Gastaut syndrome.
(3) Treatment of partial seizures (simple, complex, with or without secondary generalization).
(4) Treatment of prolonged or cluster seizures.
The guidelines group assessed all the known published and one unpublished study of interventions in adults with intellectual disability and epilepsy. Table 2 shows these studies and the mean ratings for the level of evidence provided by the group. These data will be incorporated into the recommendations.
DRUG TREATMENT Principles of drug therapy
• Ensure that the patient has received appropriate first-line treatment for their seizure type and syndrome.
• In patients still continuing to have seizures, despite appropriate first-line antiepileptic treatment:
-review diagnosis -review treatment adherence -ensure that the maximum tolerated dose has been used * If the first drug continues to be ineffective at the maximum tolerated dose, an alternative drug should be introduced slowly without tapering the first. If the patient has a good response to the second drug consider withdrawing the first drug gradually. * If reasonable options for monotherapy have been explored and acceptable symptom control is still not achieved, long-term two-drug therapy should be tried. * If the first add-on drug is not effective, replace with a second add-on drug then slowly withdraw the ineffective drug. This process can be repeated for other possible add-on drugs. * If symptoms are still not controlled on two drugs, some patients may benefit from an additional third drug. * Intermittent treatment with benzodiazepines such as clobazam or clonazepam may be useful in preventing clustering of seizures, or on days when seizures need particularly to be avoided. Used intermittently the risk of developing tolerance to the drug is reduced.
TREATMENT OF GENERALIZED SEIZURES (ABSENCE, PRIMARY GENERALISED TONIC-CLONIC, MYOCLONIC SEIZURES)
There is a paucity of monotherapy data in patients with generalized epilepsy. The grading of our recommendations reflects this situation.
Recommended first line
• Sodium valproate, lamotrigine (C, S4).
If first line is unsuccessful or unacceptable side effects
• Topiramate (C, S4).
• Carbamazepine (C, S4) (where no myoclonic or absence seizures are present).
Long term benzodiazepine use in adults with an intellectual handicap should only occur when other measures have been attempted. There are specific concerns over excessive sedation with cognitive effects, movement disorders, hypersalivation and seizures on drug withdrawal (C).
THE LENNOX-GASTAUT SYNDROME
• Lamotrigine, topiramate and felbamate can reduce atonic seizures as add-on therapy in individuals with Lennox-Gastaut syndrome (A, S4).
Lamotrigine has been shown to be effective in all seizure types associated with the Lennox-Gastaut syndrome. (A, S4).
TREATMENT OF PARTIAL SEIZURES (SIMPLE, COMPLEX, WITH OR WITHOUT SECONDARY GENERALIZATION)
Recommended first line
• Valproate, carbamazepine and lamotrigine (C, S4).
• The differential cognitive profile of lamotrigine when compared with carbamazepine may give lamotrigine an advantage in those with cognitive deficits (C, S4).
Whilst having comparative efficacy the use of phenytoin and phenobarbitone are not recommended due to their cognitive and behavioural side effects, and in the case of phenytoin the complex saturation kinetics (C, S4).
RECOMMENDED ADD-ON THERAPY
There is a dearth of evidence comparing drugs in the add-on partial epilepsy situation. A meta-analysis of add-on studies failed to differentiate between vigabatrin, lamotrigine, gabapentin, topiramate and tiagabine (A, S4). The novel antepileptic drug levetiracetam has also shown efficacy in add-on partial seizures. The recent evidence of visual field deficit in individuals on vigabatrin means that the use of this drug will be severely curtailed in the adult population 65 .
As a matter of good practice the decision should be based on the relative merits of the drug for the individual concerned: this will frequently lead to decisions made on side effect profiles.
DRUG MONITORING
Serum level monitoring of antiepileptic medication should not be performed without a clear indication. The main indications are:
• To detect or confirm treatment adherence.
• To adjust phenytoin dose.
• To avoid or identify drug-related toxicity.
• Where pharmacokinetic interactions may alter serum concentrations in unpredictable ways.
TREATMENT OF PROLONGED AND CLUSTER SEIZURES
An issue of particular importance to clinicians is the assessment of appropriate acute seizure treatment. Good evidence exists for the use of diazepam by the oral or rectal route and some evidence is appearing for the use of buccal 66 or intranasal midazolam 62 . Due to the varied care arrangements for people with an intellectual disability a structured plan for the administration of such rescue medication is essential.
Treatment of prolonged and clustered seizuresStatements and recommendations.
• Any individual who has epilepsy and intellectual disability should have an assessment of the management of prolonged seizures and/or cluster seizures.
• Where rescue medication is prescribed a care plan should be completed which must include clear guidelines on seizure duration, type and maximum daily dosage.
STANDARDS FOR SERVICES
Many individuals with an intellectual disability and epilepsy will have carers (both formal and informal) who support them. Care plans should be individualised and take account of the following.
Standards for services-recommendations and statements.
In particular services must ensure that:
• Both the medical and psychosocial impact of epilepsy is adequately assessed, and regularly reviewed.
• Carers and staff working with the individual should receive training in epilepsy and its management, and on the impact it has on peoples lives.
• Training should also be provided on methods of behavioural observation and seizure reporting.
• Carers should also be trained in any necessary emergency procedures, such as the administration of rectal medication and resuscitation, and clear policies should be provided for these on an individual basis.
• Care plans should ensure consistency in the support offered to people with intellectual disability and epilepsy. For example, the same individuals should accompany the person with epilepsy to clinic appointments.
• Accurate records should be kept, using seizure diaries or equivalents and those working with the person with epilepsy should be familiar with their use.
RISK ASSESSMENT
People with epilepsy living in various care settings will all be put at some level of risk due to their seizure disorder. The level of risk will depend upon each individual, the severity of their epilepsy and the environment surrounding them at the time of the seizure. It is important that the level of risk is assessed in order reduce the impact of the seizures on the individual's quality of life.
Risk assessment-recommendations and statements.
All individuals with epilepsy and intellectual disability should have a risk assessment covering:
(1) Bathing and showering.
(2) Management of the acute seizure.
(3) Impact of epilepsy in social settings-removing restrictions.
SUMMARY POINTS
• Epilepsy has a great impact on individuals with epilepsy and intellectual disability and their families.
• A multiprofessional approach is essential to reduce this impact.
• Seizure reduction remains the prime aim of epilepsy management in this population.
• Most intervention decisions are based on nonintellectual disability studies.
• Those studies that exist are mainly in the LennoxGastaut syndrome.
• The individuals care setting impacts on treatment application.
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